Peter Lichtlen

All filings by Peter Lichtlen on record concern Sucampo Pharmaceuticals, Inc. Over a trading history stretching from 6 March 2017 to 13 February 2018, the count stands at 2 filings.

The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.

Most recently, on 13 February 2018, the filings show a transaction worth €351k in Sucampo Pharmaceuticals, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.